Skip to content

Evaluation of the efficacy and the safety of soy protein on human muscle metabolism. -On the inpatient.

Evaluation of the efficacy and the safety of soy protein on human muscle metabolism. -On the inpatient. - Clinical trial of intake of soybean protein ingredients. -On the inpatient.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006001
Enrollment
30
Registered
2011-07-26
Start date
2014-08-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inpatient

Interventions

Sponsors

The University of Tokushima
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)The inpatient 2)Subject with Performance Status(PS)2 or 3 3)Subject must be aged =>20 years. 4)Both men and women 5)Subject who consent to participate in this study in person.

Exclusion criteria

Exclusion criteria: 1)Primary muscle disease 2)Chronic kidney disease 3)Diabetes mellitus 4)Subject who use any medication of the muscle. 5)Subject who have soybean allergy and milk allergy. 6)Subject who take the health food supplement including the soybean. 7)Pregnant female, lactating female 8)Subject who can't undergo MRI scan. 9)Subject who have been enrolled in this study within the last 2weeks. 10)The case that subject refuse to participate in this study. 11)The case that it is difficult to participate in this study in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
1)Sectional area of large hamstring muscles 2)Marker of muscle athropy(3Met-His,CK) 3)Marker of oxidative stress(8-OHdG) 4)Muscle strength

Countries

Japan

Contacts

Public ContactTakeshi Nikawa

The University of Tokushima Graduate School of Nutrition and Bioscience -Nutritional Physiology

nikawa@nutr.med.tokushima-u.ac.jp088-633-9247

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026